Managing Pharmaceutical Quality The new Paradigm for the Pharmaceutical Quality System

Programme

Where it all comes from
A brief history of pharmaceutical Quality
Review of Changes and Expectations of GMP regulations
The organisational structure, management responsibilities and the management review

EU GMP Chapter 1 and ICH Q10
The Quality Management System throughout the Product Lifecycle
Continuous and Continual Improvement
Elements of the Quality Management Review and responsibilities of Senior Management
Maintenance of cGMP: Regulatory Surveillance, Quality Manual
Quality Systems Interdependency

Integration of Non-Conformance Management and Change Management in Continuous Improvement
Understanding critical processes & where quality risks lie/ process mapping
Managing non-conformances to minimise the potential for recurrence
The importance of integration of Non-Conformance and Change Management
The role of Quality Impact Assessment & effectiveness checks
The link to Opportunities for Improvement (OFIs) and Continuous Quality Improvements (CQIs)
Meaningful metrics (and the pitfalls)

Relevant aspects of Quality Risk Management for the Evaluation of pharmaceutical Processes in Product Life Cycle
Elements for risk management are reviewed from perspective of the Product
Life Cycle (from R&D to manufacturing, surveillance and discontinuation).
The use of Quality Risk Management for evaluation of performance
measurement (KPIs) following the end-to-end product supply chain processes.

Assignment of Metrics and Correlation with Process Controls
The importance of proper use and relevance of lagging and leading KPIs is explained in correlation with the process controls.
The set up and implementation of a risk based data evaluation method is
provided for continual improvement and input for Management Review.

Case Study: The Transition Phases
In this case study a step by step process will show how a pharmaceutical
company has gone through the transition from GMP to Pharmaceutical Quality
System.

Wrap-up: What the Future will bring
True understanding of the quality risks specific to our businesses
A shift to pro-active QRM from reactive risk assessment
Integration of QRM and change management
Moving away from the functional silo mentality
Process and QMS improvement in the interest of patient care

Parallel Sessions (2 out of 3):

1. Pharmaceutical Quality System: what’s important for Global Pharma
2. Pharmaceutical Quality System: what’s important for Small Pharma
3. Elements of modern QA Organisations:
Introduction of actors and factors of importance to quality and process dynamics
Stages of identifying and mapping of key processes

You will be able to attend 2 of these sessions. Please choose the ones you like to attend when you register for the course
Meaningful performance evaluation criteria and metrics